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osting by EAbstract Objective: To determine whether appropriate dose adjustment was taken into account
or not by the physicians when prescribing drugs in patients with renal impairment.
Design: A retrospective chart review was performed and included 98 adult in-patients, diagnosed
with renal impairment based on clinical evaluation and laboratory data, in King Abdulaziz Univer-
sity Hospital (KAUH), Jeddah, Saudi Arabia, who was admitted to the hospital from September
2005 to January 2011. Data of the patients were noted and recorded including baseline demograph-
ics, clinical data, laboratory data, renal state, treatment data and medications.
Results: The initial number of the patients was reduced to 80 where a total of 502 drugs were inves-
tigated in the present study with an average of six drugs per patient. Of these 502 studied drugs, 196
(39%) required dose adjustment where 92 (46.9%) were adjusted and 104 (53.1%) were not adjusted.
It was found also that most of the drugs requiring dose adjustment were antibiotics (39.8%).
Conclusion: The current study conﬁrms that physicians still do not take into account sufﬁciently
patients’ renal function when prescribing drugs. Continuous medical education and collaboration
with clinical pharmacist should be encouraged for quality improvement in patients with renal impair-
ment.
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Table 2 Baseline characteristics of patients with chronic
kidney disease (CKD) (n= 80).
Characteristics n (%)
Sex
– Male
– Female
44 (55)
36 (45)
Median age 60
Associated diseases
– CKD+ hypertension
– CKD+ diabetes
10 (12.5)
2 (2.5)
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Kidney is the major organ for maintaining homeostasis of ﬂuid
and electrolytes and, in particular, plays an important role in the
disposition of many drugs. Chronic kidney disease (CKD) is
divided into ﬁve stages (Table 1) (Hartmann et al., 2010). It is
important to know whether a patient is suffering from renal
insufﬁciency (CKD stages 2 through 5) and, if so, at what stage,
because nearly half of all drugs or their metabolites are excreted
by the kidneys, and 30% of all adverse effects of medication
have a renal cause or a renal effect (Corsonello et al., 2005).
Therefore, the patients with renal dysfunction must be closely
monitored for the drugs that require modiﬁcations of dosages
or frequencies to prevent adverse effects (Preston et al., 1995).
The high prevalence of renal failure and the large number
of drugs with renal elimination or potential nephrotoxicity
suggest that physicians should consider renal function when
prescribing (Reed and Sabatini, 1986; Liano et al., 1996; Hunt
et al., 1998). The few studies that have assessed drug prescrib-
ing in renal impairment showed that adjustments were rarely
applied by the physicians (Cantu et al., 1992; Wong and Jones,
1998). The current study was designed to assess the prevalence
of proper applying dose adjustment by the physicians in pa-
tients with renal impairment in the university hospital in Jed-
dah, Saudi Arabia.
2. Methods
A retrospective chart review was performed at the male/female
medical ward in King Abdulaziz University Hospital (KAUH),
Jeddah, Saudi Arabia on adult patients who was admitted to
the hospital from September 2005 to January 2011. The study
was done after approval from KAUH review board and it
was conducted to assess applying dose adjustment by the phy-
sicians in patients with impaired renal function.
The study was carried out on patients diagnosed with renal
impairment based on clinical evaluation and laboratory data.
All patients with associated conditions as hypertension, diabe-
tes mellitus or other diseases or patients with kidney transplant
were enrolled in the study. The initial study group of 98 was
reduced to 80 as a result of insufﬁcient recorded data available
in 17 patients and the transfer of one patient to another hospi-
tal. Data of the patients were noted and recorded including
baseline demographics, clinical data, laboratory data (includ-
ing serum creatinine and creatinine clearance), renal state
(including degree of renal impairment and dialysis), treatment
data and medications (including drugs, dosages, concomitant
drugs and dose adjustment). Data of the study were analyzed
descriptively.
Creatinine clearance (CrCl) was calculated using the
Cockroft–Gault equation (Cockroft and Gault, 1976):Table 1 The severity of renal insufﬁciency and stages of
chronic kidney disease (CKD) (Hartmann et al., 2010).
CKD stage GFR (mL/min) Renal insuﬃciency
1 120–90 Non
2 90–60 Mild
3 60–30 Intermediate
4 30–15 Severe
5 15–0 Preterminal, requires dialysisMale : CrCl ¼ ð140 ageÞ x weight=ð72 x serum creatinineÞ
Female : CrCl ¼ ð140 ageÞ x weight
x 0:85=ð72 x serum creatinineÞ
If the actual body weight of the patient was more than
120% of the ideal body weight (IBW), the weight would be
adjusted by the formula listed as follows and be plugged into
the Cockroft–Gault equation.
IBW for male adults : IBWðkgÞ ¼ ðheightðcmÞ  80Þ x 0:7
IBW for female adults : IBWðkgÞ ¼ ðheightðcmÞ  70Þ x 0:6
Dosing weight ¼ ðactual body weight IBWÞ x 0:4þ IBW:3. Results
A total of 502 drugs in 80 patients were investigated in the current
study with an average of six drugs per patient. The mean age of
these patients was 60 years with 55% male and 45% female. All
patients have associated diseases with the highest percent having
multiple diseases including hypertension, diabetes and other dis-
eases (40%) and 5% of patients were renally transplanted. The
highest number of patients was in stage 3 (4%) (Table 2).
Of these 502 studied drugs, 196 (39%) required dose adjust-
ment where 92 (46.9%) were adjusted and 104 (53.1%) were
not adjusted (Fig. 1). The current results showed also that
most of the drugs requiring dose adjustment were antibiotics
(39.8%). Vancomycin was frequently given and ranked the
highest among antibiotics being recommended for renal dosing
adjustment. Besides, ranitidine, atenolol and furosemide were
also the highest among all drugs recommended for renal dos-
ing adjustment (Table 3).
4. Discussion
Many drugs are extensively excreted by the kidney, and there-
fore, they will accumulate in patients with poor renal function– CKD+ hypertension + diabetes
– CKD+ hypertension + diabetes + other diseases
– CKD+ other diseases rather than hypertension
or diabetes
– Patients with renal transplant
20 (25)
32 (40)
12 (15)
4 (5)
Degree of CKD
– Stage 2
– Stage 3
– Stage 4
– Stage 5
16 (20)
32 (40)
22 (27.5)
10 (12.5)
Table 3 Non-adjusted drugs in patients with renal
impairment.
Drug (n= 196) Non-adjusted n (%)
Analgesics
– Tramadol (4) 0 (0)
Antacid
– Ranitidine (14) 12 (86)
Antimicrobials
– Amikacin (8)
– Ampicillin (2)
– Augmentin (6)
– Ceftazidime (8)
– Cefuroxime (4)
– Ciproﬂoxacin (10)
– Co-trimazole (2)
– Imipenem (8)
– Meropenem (8)
– Tazocin (8)
– Vancomycin (12)
– Fluconazole (2)
0 (0)
0 (0)
6 (100)
8 (100)
0 (0)
0 (0)
2 (100)
8 (100)
8 (100)
0 (0)
12 (100)
0 (0)
Antidiabetcs
– Glibincamide (2)
– Gliclazide (2)
– Metformin (4)
2 (100)
0 (0)
0 (0)
Antiemetics
– Domperidone (2)
– Metoclopramide (4)
0 (0)
4 (100)
Antigout
– Allopurinol (4)
– Colchicine (4)
2 (50)
4 (100)
Cardiovascular drugs
– Aspirin (16)
– Atenolol (10)
– Digoxin (4)
– Enalapril (2)
– Bisoprolol (4)
4 (25)
10 (100)
4 (100)
0 (0)
2 (50)
Diuretics
– Furosemide (30)
– Hydrochlorothiazide (6)
10 (34)
6 (100)
Immunosuppressants
– Mycophenolate (6) 0 (0)
0
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Figure 1 Adjusted and non-adjusted drugs in patients with renal
impairment.
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For these drugs, dosage adjustment according to renal func-
tion is indicated in order to avoid overdosage and iatrogenic
risk of renal impairment or its aggravation (Alkhuniazi and
Schrier, 1996). Physicians should pay careful attention when
considering drug therapies with active or toxic metabolites that
can accumulate and contribute to exaggerated pharmacologic
effects or adverse drug reactions in patients with chronic kid-
ney disease (Munar and Singh, 2007). It should also be noted
that product information sheets often have only crude dosing
guidelines for renal impairment and sometimes speciﬁcally
exclude patients with renal impairment, usually because these
patients were excluded from the primary studies (Doogue
and Polasek, 2011).
The current study showed that 53.1% of the drugs that re-
quire adjustment were not adjusted by the physicians’ orders.
In a similar study conducted in a public hospital in Paris,
France, Salomon et al., 2003, found that 34% of the ordered
medications by the physicians were inappropriate. Several
explanations may be elucidated for this lack of dose adjust-
ment. These include physicians’ underestimation of the conse-
quences of mild renal impairment in terms of subsequent
iatrogenic risks or their poor knowledge of the medications
requiring adjustment in renal impairment (Dryer, 1977).
Although used in daily practice, serum creatinine level is often
inappropriate to assess actual renal function and leads to
underestimation of renal impairment, particularly in elderly.
The assessment of creatinine clearance with Cockroft–Gault
equation, taking into account patient’s weight, age and serum
creatinine provides an accurate assessment of renal function
(Cockroft and Gault, 1976). Another explanation is that phy-
sicians do not calculate creatinine clearance and underestimate
the necessity of adjusting medication dosage.
The present study showed also that most of the drugs
requiring dose adjustment were antibiotics especially vancomy-
cin. This ﬁnding was in accordance with that found by Hou
et al., 2011, in Taiwan, with gentamicin as the most ranked
antibiotics.
It is important to realize that the necessary dose adjustment
could be calculated proportionally to the changed elimination
rate (and thus inversely proportionally to the half-life). Either
the dose of a drug must be reduced in inverse proportion to the
half-life, or else the interval between doses must be prolonged
proportionally to the half-life (Aronoff, 1999). If, for example,
the half-life of a drug is ﬁve times longer because of renalinsufﬁciency, its dose should be reduced to 20% of the normal
dose (1/5 = 0.20). If the dose is thus reciprocally lowered and
the interval between doses is unchanged, then the area under
the curve will be the same as in the normal case, but with high-
er trough values which are what is customarily measured in
drug monitoring. This can easily lead physicians unfamiliar
with the relevant pharmacokinetics to draw false conclusions
and then reduce the dose of the drug still further, e.g., in the
case of vancomycin. In order to achieve effective levels in pa-
tients with renal failure, the trough values of vancomycin
should lie between 10 and 15 mg/L (Hartmann et al., 2010).
Beside patient outcome improvement with dose adjustment,
we can also beneﬁt from cost saving medication. As an exam-
ple, if vancomycin 500 mg/vial that was highly ranked in the
current study was adjusted from one vial every 12 h to one vial
once daily; hence, one vial will be saved every day.
The main limitation of the present study was that it was a
retrospective study lacking the direct contact and observation
220 A.M. Alahdal, A.A. Elberryof the patients, and some data about the patients and dialytic
state were not included in all ﬁles. Moreover, the study was
performed only in one hospital, so, a large multicenter study
may be needed in the future.
5. Conclusion
The current study showed that physicians still do not pay en-
ough attention to the need of dose adjustment for most drugs
in patients with renal impairment. Continuous medical educa-
tion of the physicians and collaboration with clinical pharma-
cist is an important issue for quality improvement regarding
renally impaired patients.
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